Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Not applicable

ALAS PROPIAS: BMGIM for Professionals Working in Intimate Partner Machista Violence Services

NCT07925736 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2026-04-21
Last updated
2026-11-09

Condition(s) studied

Burnout SyndromePsychological Well-being

Investigational drug(s) / intervention(s)

ALAS PROPIAS - Individual Music Therapy BMGIM

ALAS PROPIAS - Individual Music Therapy BMGIM: The ALAS PROPIAS intervention consists of 10 individual music therapy sessions using the Bonny Method of Guided Imagery and Music (BMGIM), aimed at professionals working in services supporting women experiencing machista violence in intimate partner relationship. The intervention focuses on exploring imagery, emotions, and sensations through guided music listening, followed by a process of integration and reflection. The program aims to evaluate changes in burnout, compassion fatigue, vicarious trauma, secondary traumatic stress, anxiety, positive and negative affect, emotional regulation, psychological well-being, and professional well-being among participants.

Study summary

This study evaluates the impact of a 10-session individual music therapy intervention using the Bonny Method of Guided Imagery and Music (BMGIM) on the well-being and psychological health of professionals working in services supporting women experiencing intimate partner machista violence.

The study uses a controlled, non-randomized quasi-experimental design, with an experimental group and a wait-list control group. Changes in burnout, compassion fatigue, vicarious trauma, secondary traumatic stress, anxiety, positive and negative affect, emotional regulation, and professional well-being are assessed.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Professionals working in centers or shelters supporting women experiencing intimate partner machista violence. * Direct professional contact with cases of intimate partner violence. * Interest in participating in the individual BMGIM intervention and provision of informed consent. Exclusion Criteria: * Active psychosis. * Unstabilized suicidal crisis. * Uncontrolled substance use that prevents participation. * Inability to attend weekly sessions

Primary outcome measure(s)

  • Change in Burnout — Baseline (T0), Immediate Post-intervention (T1), 3-month Follow-up (T2)
    Burnout will be assessed using the Spanish adaptation of the Maslach Burnout Inventory (MBI) (Maslach \& Jackson, 1981; Seisdedos, 1997). Scores at the final assessment will be compared with baseline scores to evaluate changes in burnout among participants in the experimental and wait-list control groups.
  • Change in Positive and Negative Affect — Baseline (T0), Immediate Post-intervention (T1), 3-month Follow-up (T2)
    Positive and negative affect will be assessed using the Spanish adaptation of the Positive and Negative Affect Schedule (PANAS) (Sandín et al., 1999). Scores at the final assessment will be compared with baseline scores to evaluate changes in positive and negative affect in the experimental and wait-list control groups.
  • Change in Psychological Well-Being — Psychological well-being will be assessed using the Spanish adaptation of Ryff's Psychological Well-Being Scales (Díaz et al., 2006). Scores at the final assessment will be compared with baseline scores to evaluate changes in psychological well-being in
    Psychological well-being will be assessed using the Spanish adaptation of Ryff's Psychological Well-Being Scales (Díaz et al., 2006). Scores at the final assessment will be compared with baseline scores to evaluate changes in psychological well-being in the experimental and wait-list control groups.
  • Change in Professional Quality of Life — Baseline (T0), Immediate Post-intervention (T1), 3-month Follow-up (T2)
    Professional quality of life will be assessed using the Spanish adaptation of the Professional Quality of Life Scale, version 5 (ProQOL-5) (Galiana et al., 2020). Scores at the final assessment will be compared with baseline scores to evaluate changes in professional quality of life in the experimental and wait-list control groups.
  • Change in Secondary Traumatic Stress — Baseline (T0), Immediate Post-intervention (T1), 3-month Follow-up (T2)
    Secondary traumatic stress will be assessed using the Secondary Traumatic Stress Scale (STSS) (Guerra \& Saiz, 2007). Scores at the final assessment will be compared with baseline scores to evaluate changes in secondary traumatic stress in the experimental and wait-list control groups.

Trial sites (1)

FacilityCityRegionStatus
Universidad Miguel Hernández de Elche Elche Alicante
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07925736 on ClinicalTrials.gov ↗ ← All trials in Spain